Bio Break: Laboratory Developed Tests vs. In Vitro Diagnostics

Resources

Bio Break: Laboratory Developed Tests vs. In Vitro Diagnostics

Sector: Diagnostics
Topic: Bio Break

In this episode of Bio Break, Joris van der Heijden and Nick Allan dive into the FDA’s new regulations surrounding Laboratory Developed Tests (LDTs) and their impact on the medical device industry. As LDTs grow in complexity, including applications like genetic testing and AI-driven diagnostics, these regulatory changes mark a significant shift for laboratories, developers, and healthcare providers.

Nick, drawing on his experience with medical device development, explains the critical distinctions between LDTs and In Vitro Diagnostics (IVDs). He provides insights into why these changes are happening and what they mean for developers working to bring innovative diagnostic tools to market.

Key takeaways from the episode include:

  • Understanding the Difference: LDTs are clinically validated tests performed in CLIA-approved labs but do not require FDA regulatory clearance, unlike IVDs, which are classified as medical devices.
  • The Shift in Regulation: The FDA is transitioning from selective enforcement to increased scrutiny due to the growing complexity and impact of LDTs, such as cancer diagnostics and genetic testing.
  • Implications for Developers: Nick explores how the new regulations add layers of oversight but also improve the safety, accuracy, and reliability of tests with far-reaching implications for patient care.

Joris and Nick discuss the broader industry impacts, including the challenges and opportunities presented by these regulatory changes. While some pushback is expected, they highlight how these steps are ultimately beneficial for innovation and patient outcomes, ensuring that advanced diagnostics meet higher standards of clinical utility and reliability.

This episode is essential viewing for medical device developers, diagnostic innovators, and healthcare professionals navigating the evolving regulatory landscape. Gain a clear understanding of how the FDA’s increased involvement in LDTs is shaping the future of diagnostics and how to stay ahead in this rapidly changing environment.

Laboratory Developed Tests vs. In Vitro Diagnostics

Read our article on the impact of FDA Laboratory Developed Tests 2024 Policy update to its regulatory approach for in vitro diagnostic products (IVDs), including laboratory developed tests (LDTs). 

A healthcare professional in a sterile gown and gloves holds an endoscope, with a red arrow pointing toward the device. Beside it, a handheld cleaning brush is shown, symbolizing the manual cleaning process. Text overlay reads “Not sterile. Just safe?”

Understanding Endoscope Reprocessing

Ariana and Mark examine the complexities of endoscope reprocessing, one of the most difficult tasks in medical device hygiene.

Technician operating a custom aluminum-framed drop test rig with a white platform and green background wall.

Medical Device Drop Testing in Action

Medical device drop testing helps ensure that products and packaging survive real-world handling. We demonstrate in-house drop testing on an actual device and its packaging using a custom-built drop tester.

Balancing the needs of startup and enterprise medical device partners in CDMO projects.

Unique Startup, Founder and Enterprise CDMO Needs

Medical device startups/founders and enterprise partners have unique strengths and goals, which are often reflected in the way they work with CDMO (Contract Development and Manufacturing Organizations) partners.

Technician using digital calipers to validate component dimensions during medical device testing.

Test Method Validation in Medical Device Development

In the highly regulated world of medical device development, ensuring product safety, quality, and compliance is essential. One critical yet often overlooked aspect of this process is test method validation (TMV) in medical device development.